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Dissolution improvement of solid self-emulsifying drug
delivery systems of fenofi brate using an inorganic high surface 
adsorption material
Solidifi cation of lipid formulations using adsorbents is a 
recent technique a racting great interest due to its favour-
able properties including fl exibility in dose division, reduc-
tion of intra-subject and inter-subject variability, improve-
ment in effi  cacy/safety profi le and enhancement of physical/
chemical stability. The current study aims to convert liquid 
self-emulsifying/nanoemulsifying drug delivery systems 
(SEDDS/SNEDDS) into solid SEDDS/SNEDDS and to assess 
how adsorption of the drug onto an inorganic high surface 
area material, Neusilin® grade US2 (NUS2), aff ects its in vi-
tro dissolution performance. Lipid formulation classifi ca-
tion systems (LFCS) Type III formulations were designed 
for the model anti-cholesterol drug fenofi brate. NUS2 was 
used to solidify the SEDDS/SNEDDS. Particle size and SEM 
analyses of solid SEDDS/SNEDDS powder were carried out 
to investigate the adsorption effi  ciency. In vitro dissolution 
studies were conducted to compare the developed formula-
tions with the marketed product. The results of character-
ization studies showed that the use of 50 % (m/m) adsorbent 
resulted in superior fl owability and kept the drug stable is 
amorphous state. Dissolution studies allow the conclusion 
that the formulation containing a surfactant of higher wa-
ter solubility (particularly, Type IIIB SNEDDS) has compa-
rably faster and higher release profi les than Type IIIA 
(SEDDS) and marketed product.
Keywords: self-emulsifying/nanoemulsifying drug delivery 
systems, fenofi brate, in vitro dissolution test, solidifi cation 
technique, adsorption
Lipid-based dosage forms have gained high priority and become more prominent in 
the pharmaceutical industry in recent years (1–4). Lipids have been used as carriers in 
various delivery systems for drug administration, including solutions, suspensions, emul-
sions, self-emulsifying systems, microemulsions and, recently, solid dosage forms (via 
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technology conversion) such as solid self-emulsifying systems. They are designed to in-
crease the solubility and bioavailability of drugs belonging to the BCS classes II and IV, in 
which the dissolution rate is the limiting factor for absorption (5–8). Lipid-based carriers 
are usually liquid at room temperature and are generally encapsulated into so /hard gel-
atin capsules for fi nal oral delivery. This could be a great challenge since the interaction 
between the liquid formulation and capsule shell may result in either bri leness or so -
ness of the shell (9). In addition, the stability of liquid formulations could be another major 
issue (e.g. leaching and rancidity), since some drugs might suff er signifi cant chemical in-
stability in both aqueous and oily formulations.
To address this limitation, incorporation of liquid lipid formulations into a solid dos-
age form is therefore convincing and desirable. Liquid lipid formulations could be trans-
formed into acceptable free fl owing powder by loading the formulation onto a suitable 
solid carrier (10, 11). Solid dispersions and in particular self-emulsifying drug delivery 
systems (SEDDS) have proved to be the most practical route to commercialization. Success 
of Fortovase® (Saquinavir), Norvir® (Ritonavir) and Neoral® cyclosporine as lipid suspen-
sions have prompted formulators to develop more stable forms by converting these sus-
pensions into powder (12). Neusilin®’s high specifi c area, increased surface adsorption, 
porosity, anticaking, fl ow enhancing properties and its ability to keep the drug stable 
under amorphous state make it one of the best choices among the adsorbents available 
today (13). Good understanding of the characteristics of lipid excipients and their perfor-
mance in formulations is desirable to rank and select suitable excipients in formulation 
development.
Fenofi brate is a lipid-regulating agent that has chemical, pharmacological, and clinical 
similarities to other fi brate drugs such as clofi brate and gemfi brozil (14). Fenofi brate is a 
BCS class II drug with a high dose number (15). It can be assumed that the low oral bio-
availability of fenofi brate is due to its solubility and dissolution limitations. It is a non-
electrolyte with low aqueous solubility (< 3 µg mL–1) and fairly high octanol/water parti-
tion coeffi  cient (log P 4.6).
Eff orts to develop tablet formulations containing suffi  cient quantities of lipid and sur-
factant excipients to solubilize poorly soluble drugs have met with limited success due to 
the tendency of these excipients to compromise the physical integrity and mechanical 
strength of conventional compressed tablets. To achieve extensive absorption of a poorly 
water soluble compound from the GI tract requires an innovative formulation approach. 
Encapsulation of formulations such as liquids or semi-solids provides opportunities for 
delivering poorly water-soluble compounds with reproducible absorption and acceptable 
bioavailability.
While an enormous amount of industrial interest exists in transforming such liquid 
lipid formulations into free-fl owing powders that are compatible with direct tablet press-
ing, only a limited number of studies have been conducted to investigate the solidifi cation 
of lipid formulations; they have been focused on their adsorption onto inorganic high 
surface area materials. The goal of the current research is to assess how the adsorption of 
drug loaded SEDDS/SNEDDS onto an inorganic high surface area material (Neusilin® 
grade US2) aff ects its in vitro (dissolution) performance.
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All chemicals used in the studies were obtained from commercial suppliers. Fenofi -
brate (2-[4-(4-chlorobezoyl) phenoxy]-2-methylpropionic acid 1-methylethyl ester) was sup-
plied by Sigma-Aldrich Co, USA. Miglyol 812 (M812), Imwitor 988 (I988), Imwitor 308 (I308) 
and propylene glycol (PG, 98 % pure) were supplied by Sasol Germany GmbH, Germany. 
The non-ionic surfactants used were TO-106V (PEG 6 sorbitan monooleate, HLB-10) and 
HCO-30 (PEG 30 hydrogenated castor oil, HLB-11), supplied by Nikko Chemicals Co., Ja-
pan. All excipients were used without further purifi cation. Cremophor EL (CrEL, polyoxy-
ethylene 35 castor oil), and Cremophor RH40 (CrRH40, polyoxyethylene 40 castor oil) were 
from Sigma Chemical Co. (USA). Neusilin® grade US2 (NUS2, synthetic magnesium alu-
minometasilicate, Fuji Chemical Co., Japan) was used as the microporous adsorbent to load 
SEDDS/SNEDDS. Lipanthyl® (marketed product of fenofi brate, 200 mg micronized cap-
sule) manufactured by Abbo  (USA) was used in the study. Water used in this study was 
obtained from a Milli-Q water purifi cation system (Sartorius, Germany). All other chemi-
cals and solvents were of analytical purity.
Methods
Design of liquid SEDDS/SNEDDS. – Within the current scope of the study, self-emulsi-
fying lipid formulations, particularly SEDDS/SNEDDS, have been developed using lipid 
formulation classifi cation systems (LFCS). LFCS was proposed by Pouton in 2000 in four 
categories (16) to gain knowledge of excipient selection and compare the performance of 
various lipid-based drug delivery systems. Hence, LFCS type IIIA and IIIB lipid-based 
formulations (SEDDS/SNEDDS) have been prepared in two component systems with vary-
ing oil and surfactant concentrations. For systems which involved a blend of two oils with 
a surfactant, the strategy was to weigh and combine a primary mixture of the two oil 
components. For example, a mixture of M812 and I988 (7:3, by mass) was prepared and 
then blended with 50 % surfactant. The mixture was thoroughly blended with a Vm1 vor-
tex (Ratek Instruments Pty. Ltd., Victoria, Australia), with heating if necessary, to ensure 
uniformity. The formulations were prepared using 5-g capacity vials and were tightly 
sealed until further use.
Droplet size distribution of liquid SEDDS/SNEDDS. – The droplet size distribution of 
diluted SEDDS/SNEDDS was measured by laser diff raction analysis using Zetasizer (Nano 
ZS, Germany) particle sizing systems (17). The formulations were diluted at a ratio of 
1:1000 V/V (SEDDS/SNEDDS : distilled water) and mixed for 1 min before analysis. Samples 
were placed directly into the module and measured 10 times. Particle size was calculated 
from the volume size distribution. All experiments were performed in triplicate and good 
agreement was found between measurements. As reported earlier, the self-emulsifying 
effi  ciency is strongly associated with the mean droplet size of the produced emulsion (18, 
19).
Preparation of solid SEDDS/SNEDDS. – The liquid SEDDS/SNEDDS was added gradu-
ally and blended with the adsorbent NUS2 at the following fi xed fi nal SEDDS/SNEDDS to 
adsorbent appropriate mass ratio of 50/50, 60/40 and 70/30 (%, m/m). Briefl y, a fi xed amount 
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of liquid SEDDS/SNEDDS was initially added to and mixed with NUS2 (20). The batch size 
of each blend was varied according to the quantity of the adsorbent and was categorized 
based on the fl owability of the powder. The fl ow behaviour of the adsorbed blend was as-
sessed visually only to measure if a non-fl owing cohesive mass was formed.
Characterization of solid SEDDS/SNEDDS powder. – Particle size, shape and bulk den-
sity aff ect the fl owability of powder material. The angle of repose for the solid SEDDS/
SNEDDS was measured to determine the fl owability of the powder (21). Briefl y, a glass 
funnel was fi  ed at a fi xed height (H) and its tip was distanced from wax paper placed on 
a horizontal surface. Solid powder was transferred through the funnel to the surface until 
the apex of the conical pile reached the tip of the funnel. The test result was calculated as 
follows:
 angle of repose = tan α = H/r
where r is the radius of the conical pile and α is the angle of repose.
Particle size determination of solid SEDDS/SNEDDS. – Size distribution of the drug load-
ed solid SEDDS/SNEDDS powder was investigated using laser light diff raction (Master-
sizer Scirocco 2000, Malvern Instruments, UK). For a typical experiment, about 300 mg of 
the drug loaded solid SEDDS/SNEDDS powder was fed into the sample micro feeder. All 
samples were analyzed 5 times and average results were taken. The sizes below 10 % 
[d(0.1)], 50 % [d(0.5)] and 90 % [d(0.9)] of the pellet were used to characterize the pellets size 
distribution. The mean diameter was taken as the average of d(0.1), d(0.5), and d(0.9) values.
X-ray diff raction (XRD). – Powder crystallinity was assessed by a multipurpose X-ray 
diff ractometer (Ultima IV, Rigaku, Japan). The samples were analyzed using CuKα radia-
tion of wavelength 1.54056 Å, generated at 40 kV voltage, 40 mA current and receiving slit 
of 0.3 mm. Analyses were preformed over 2θ range of 3–60° with an angular increment of 
0.5° min and scan step time of 1.0 s.
Diff erential scanning calorimetry (DSC). – DSC analyses of powdered samples were con-
ducted using DSC-60, Shimadzu, Japan. The samples (3–5 mg) were hermetically sealed in 
aluminum pans and heated at a scanning rate of 10 °C min–1 under dry nitrogen fl ow (30 
mL min–1) over a temperature range of 0–200 °C. Pure water and indium standard were 
used to calibrate the DSC temperature and enthalpic scale. Data from the thermal analysis 
were recorded using the Shimadzu so ware program in a TA 50I PC system.
Scanning electron microscopy (SEM). – Surface morphology of the raw drug, NUS2 and 
solid SEDDS/SNEDDS powder was visualized by SEM (Jeol JSM 5400LV SEM, Japan) oper-
ated at 15 kV. The samples were spu er-coated with a thin gold (SPI spu er coater, PA19380, 
USA) palladium layer under an argon atmosphere in a high vacuum evaporator and im-
ages were then acquired from the system.
In vitro dissolution studies. – The in vitro dissolution studies of the representative solid 
SEDDS/SNEDDS powder were fi lled in capsules (size 0) for the experiment. Dissolution of 
solid SEDDS/SNEDDS, pure fenofi brate powder and the marketed fenofi brate capsule (200 
mg Lipanthyl) was monitored using an automated dissolution tester (Logan Instrument 
Corp, USA) coupled to an automated sample collector (SP-100 peristaltic pump Logan). The 
standard USP II (apparatus 2) (paddle type, Model UDT-804, Logan) paddle method was 
used at 50 rpm and 37 ± 0.5 °C. Dissolution media (900 mL) of pH 1.2 and pH 7.4 were se-
lected to mimic the physiological pH of the GIT. Samples were collected periodically a er 
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15, 30, 45, 60, 90, and 120 min and replaced by freshly prepared dissolution medium. A er 
fi ltration through a microfi lter (0.45 µm), fenofi brate in the withdrawn samples was ana-
lyzed at 288 nm by UHPLC (Dionex, ultimate 3000, Thermo Scientifi c, USA) using an ap-
propriate solvent. Chromatographic separation was performed on a reversed-phase 
Acquity ® BEH C18 column (1.7 µm particle size, 50 mm × 2.1 mm ID) at 30 ˚C with an iso-
cratic elution profi le. The mobile phase consisting of ethanol and water (70:30, %, V/V) at a 
fl ow rate of 0.3 mL min–1 was used. All experiments were carried out in triplicate.
RESULTS AND DISCUSSION
Composition of lipid-based SEDDS/SNEDDS systems using various concentrations of 
oil and surfactant are presented in Table I. There are most interesting formulation systems 
within the lipid formulation classifi cation systems (LFCS), which are likely to produce 
nanoparticle formulations.
Droplet size analysis of liquid SEDD. – Self-emulsifi cation of mixtures containing me-
dium chain mono/di/tri-glycerides [M812:I988 (7:3)] with water insoluble surfactant (TO-
106V and/or HCO-30) showed the particle size above 50 nm, and were thus represented as 
SEDDS (Table II). On the other hand, similar oil compositions [M812:I988 (7:3)] with water 
soluble surfactant (CrEL and or CrRH40) showed a particle size lower than 50 nm, and 
were represented as SNEDDS (Table II). The apparent particle size distributions of polar 
oil I308 with all the representative surfactants in the formulations were found to be lower 
than 50 nm (Table II), producing nanodispersions at surfactant concentrations of 50 %; the 
dispersion nature of all the formulations was homogeneous upon aqueous dilution even 
though SNEDDS3 and SNEDDS4 produced more heterogeneous particles, which was 
shown by the higher PDI values (see Table II). However, oil and surfactant used in both 
Table I. Oil and surfactant composition of liquid SEDDS/ SNEDDS formulations
LFCS
type
Oil (%, m/m) Surfactant (%, m/m)
M812 I988 I308 TO106V HCO30 CrEL CrRH40
IIIA 35 15 50
IIIA 35 15 50
IIIA 35 15 50






























G. Shazly and K. Mohsin: Dissolution improvement of solid self-emulsifying drug delivery systems of fenofi brate using an inor-
ganic high surface adsorption material, Acta Pharm. 65 (2015) 29–42.
 
SEDDS and SNEDDS produced the fi nest emulsions but a limited particle size diff erence 
between them is not likely to determine the diff erences between their performances in 
vivo.
Analyses of solid SEDDS
Particle size determination of solid SEDDS. – The z-average diameter and volume mean 
distribution of the solid SEDDS/SNEDDS powder, according to the percentage of adsorbent 
NUS2 added in the liquid formulations, are presented in Table III. The z-average diameter 
was measured a er the solid powder was dispersed in water and then fi ltered (using a 
0.22-µm fi lter). In most of the formulation systems, the particle size was reduced with the 
increase in NUS2 content. In addition, it was found by visual determination that the use 
of 50 % NUS2 showed good fl owability of the powders.
Measurement of the angle of repose. – In the current studies, ratios of liquid SEDDS/
SNEDDS to NUS2 of 1:1, 1.5:1, and 2.3:1 produced dry free fl owing powders. There were no 
substantial changes between these ratios due to the high adsorption capacity of the adsor-
bent (NUS2) and retention of liquid SEDDS/SNEDDS in their intra-particular pores. On 
visual inspection, all powders were dry and free flowing at this point. However, the liquid 
SEDDS/SNEDDS-to-NUS2 ratios of 1:1 and 1.5:1 were be er than 2.3:1 (Table IV). This sug-
gests that the selection of 1.5:1 ratio would be ideal for good fl owability of the solid SEDDS/
SNEDDS powder and high drug loading for fenofi brate.
X-ray diff raction analysis. – XRD studies were performed to justify the physical nature 
of the drug in solid SEDDS/SNEDDS formulations. Fig. 1 depict the XRD spectra of pure 
fenofi brate, NUS2 and the representative solid SEDDS/SNEDDS formulations. Pure feno-
fi brate showed sharp peaks in the spectra, which were obtained at 13.79, 15.21, 20.05, 22.58, 
31.76, and 50.12 °C (2θ), due to the native crystalline form of the drug. There were no peaks 
in NUS2 and representative SEDDS/SNEDDS formulations. Hence, the disappearance of 
drug peaks in the representative solid SEDDS/SNEDDS formulations established the pres-
ence of fenofi brate in amorphous form.
Diff erential scanning calorimetry (DSC). – The generated DSC thermograms of pure fe-
nofi brate, adsorbent NUS2, and the representative solid SEDDS/SNEDDS formulations are 
Table II. Mean particle size of the drug loaded liquid SEDDS/SNEDDS of diff erent types of formulations 




SEDDS1 M812:I988(7:3)/TO-106V (1/1) 106.85 219.90 0.266
SEDDS2 M812:I988(7:3)/HCO-30 (1/1) 113.04   66.97 0.138
SNEDDS1 M812:I988(7:3)/CrEL (1/1) 116.80   39.90 0.076
SNEDDS2 M812:I988(7:3)/CrRH40 (1/1) 112.30   40.27 0.350
SNEDDS3 I308/HCO-30 (1/1)   81.90   50.29 0.594
SNEDDS4 I308/CrEL (1/1)   85.59   36.03 0.702
SNEDDS5 I308/CrRH40 (1/1)   80.18   49.05 0.222
c pdi – polydispersity index is a measure of the heterogeneity of sizes of particles in a mixture.
b Mean, n = 3; RSD < 5 %.
a Fenofi brate was loaded in the formulations at 80 % of equilibrium solubility.
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Table III. Particle size measurement of drug loaded solid SEDDS/SNEDDS powder and dispersanta
Formulation NUS2(%, m/m)
Particle size of dispersant 
(nm)c















40   98.35 769.13








30   98.80 913.21
40   76.95 921.58
50   75.81 739.03
I308/CrEL
(1/1)- SNEDDS4
70   77.45 857.63
60   60.37 876.78
50   54.89 787.44
I308/CrRH40
(1/1)- SNEDDS5
70   65.56 907.84
60   59.23 767.58
50   54.35 571.54
a Liquid SEDDS/SNEDDS, 1:1000 dilutions in water.
b NUS2 was used at various ratios in the lipid formulation and fenofi brate was loaded at 80 % of equilibrium solubility.
c Mean, n = 3; RSD < 10 %.
Table IV. Flow properties of powders a er adsorption of liquid formulations onto Neusilin® US2 at various ratios 
Liquid formulationa Liquid formulation : NUS2 Angle of repose Flowability
F1 1:1 32.8 good
F2 1.5:1 34.5 good
F3 1:1 33.5 good
F4 1.5:1 38.5 fair
F5 1:1 34.5 good
F6 1.5:1 37.5 fair
F7 2.3:1 42 pass.
F8 2.3:1 42 pass.
F9 2.3:1 42 pass.
a F1/F2/F7 – liquid formulation of SEDDS1, F3/F4/F8 – liquid formulation of SEDDS2, F5/F6/F9 – liquid formulation 
of SNEDDS3
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shown in Fig. 2. A sharp endothermic peak of pure fenofi brate was observed at 81.25 °C. 
However, there were no peaks for NUS2 and solid SEDDS/SNEDDS formulations. This 
suggests that fenofi brate converted from crystalline to amorphous state during the prepa-
ration of solid SEDDS/SNEDDS using NUS2.
Scanning electron microscopy. – The scanning electron micrographs in Fig. 3a showed 
fenofi brate as a crystalline powder with irregularly shaped crystals. Surface morphology 
of the NUS2 and solid SEDDS/SNEDDS formulations shown in Figs. 3b-e was found homo-
geneous, uniform and smooth.
In vitro dissolution studies. – In vitro release profi les of fenofi brate from the representa-
tive solid SEDDS-1 [M812:I988 (7:3)/TO-106V (1/1)], SEDDS-2 [M812:I988 (7:3)/HCO-30 (1/1)], 
and SNEDDS3 [I308/HCO30 (1/1)], control (fenofi brate raw powder) and marketed product 
(Lipanthyl®) in HCl (pH 1.2) at 37 °C are shown in Fig. 4. It is evident that the percentage 
Fig. 2. DSC thermograms of: a) pure fenofi brate, b) pure adsorbent NUS2, c) solid SEDDS-1/NUS2 
50:50 % (m/m), d) solid SEDDS-2/NUS2 50:50 % (m/m), e) solid SNEDDS-3/NUS2 50:50 % (m/m).
Fig. 1. X-ray powder diff raction spectra of: a) pure fenofi brate, b) Neusilin US2, c) solid SEDDS-1/ 
NUS2 50:50 % (m/m), d) solid SEDDS-2/NUS2 50:50 % (m/m), e) solid SNEDDS-3/NUS2 50:50 % (m/m).
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Fig. 3. Scanning electron micrographs of: a) pure fenofi brate, b) Neusilin US2 (NUS2) raw material, c) 
solid SEDDS-1/NUS2 50:50 % (m/m), d) solid SEDDS-2/NUS2 50:50 % (m/m), e) solid SNEDDS-3/NUS2 
50:50 % (m/m), at diff erent magnifi cations.
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of fenofi brate released from both fenofi brate raw powder and Lipanthyl® is very low 
(around 17 %). In comparison, solid SEDDS-1 systems (F1, F2 and F7, Fig. 4) enhanced the 
dissolution rate of fenofi brate by 50 % within 120 minutes.
Similarly, Fig. 4b compares the in vitro release profi les of fenofi brate from F3, F4, F8, 
control (fenofi brate raw powder) and Lipanthyl®. It was found that formulations F3, F4 and 
F8 exhibited higher release (50–56 %) compared to both the control and Lipanthyl (15 %). 
Regarding the release of fenofi brate from formulations F1, F2 and F7, it was found that 
formulation F1 (50 % NUS2) showed higher release than formulations F2 and F7. This is 
evident from the similar results obtained when comparing fenofi brate release from F5, F6 
and F9 (Fig. 4c).
The overall comparison of the in vitro dissolution profi les of fenofi brate from all solid 
SEDDS/SNEDDS (except F1, F2 and F7) was over 50 % in 60 min and was signifi cantly 
higher than the release from the control and marketed product Lipanthyl® (15 %). In case 
of formulations F1, F2 and F7, the drug release was lower or delayed, which could be due 
to the water insoluble surfactant used in designing liquid SEDDS1 [(M812:I988 (7:3)/TO106V 
(1/1)]. The overall results of all the solid SEDDS/SNEDDS showed that the maximum per-
centage of drug release was achieved within 15 min.
On the other hand, in vitro dissolution studies performed in the basic medium (pH 7.4 
shown in Figs. 5a–c for the same formulations F1–F9, fenofi brate raw powder and Lipan-
thyl® are presented in Fig. 3. In case of formulations F1, F2 and F7, the drug release was 
faster and the dissolution effi  ciency was higher compared to the control and Lipanthyl®. 
Cumulative percentage release from solid SEDDS (F1) was found to be more than 45 %, 
within 60 min and was signifi cantly higher than that of the control and Lipanthyl® (17 %). 
From the overall release data in the slightly basic medium it followed that all the formula-
tions (F1–F9) showed higher release rate of fenofi brate compared to fenofi brate raw powder 
and Lipanthyl®. In all cases of the solid SEDDS/SNEDDS, almost 45 % of the drug was re-
leased within 15 min during the studies. Within all solid formulations, the use of 50 % 
NUS2 (F1, F3 and F5) gave be er fenofi brate release profi les.
The overall drug release profi le of solid SEDDS and SNEDDS in the current investiga-
tion showed that all the developed formulations (F1–F9) had higher drug release profi les 
Table V. Conversion of liquid formulations into solid SEDDS/SNEDDS using Neusilin US2 for in vitro 
dissolution studies
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Fig. 4. In vitro release of fenofi brate from the representative LFCS type III formulation in HCl pH 1.2 
at 37 °C: a) solid SEDDS-1 (F1, F2, F7), control (fenofi brate raw powder) and marketed product (Lipan-
thyl®), b) solid SEDDS-2 (F3, F4, F8), control (fenofi brate raw powder) and marketed product (Lipan-
thyl®), c) solid SNEDDS3 (F5, F6, F9), control (fenofi brate raw powder) and marketed fenofi brate (Li-
panthyl®). Mean values, n = 3.
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Fig. 5. In vitro release of fenofi brate from the representative LFCS type III formulation in phosphate 
buff er pH 7.4 at 37 °C: a) solid SEDDS-1 (F1, F2, F7), control (fenofi brate raw powder) and marketed 
product (Lipanthyl®), b) solid SEDDS-2 (F3, F4, F8), control (fenofi brate raw powder) and marketed 
product (Lipanthyl®), c) solid SNEDDS3 (F5, F6, F9), control (fenofi brate raw powder) and marketed 
fenofi brate (Lipanthyl®). Mean values, n = 3.
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than the fenofi brate raw powder and marketed product Lipanthyl®. The results suggest 
that the solid SEDDS/SNEDDS formulation systems preserved the improvement of in vitro 
dissolution of liquid SEDDS/SNEDDS.
CONCLUSIONS
A large surface area material NUS2 with exceptional excipient properties for improv-
ing drug delivery was used as the microporous adsorbent to load SEDDE/SNEDDS. The 
solid state characterization studies indicate that the SEDDS2 and SNEDDS3 [(M812:I988 
(7:3)/HCO30 (1/1), I308/HCO30 (1/1)] using 40–50 % NUS2 proved to be free fl owing fi ne 
powders in stable form and the potential systems for high drug loading.
All the solid SEDDS/SNEDDS showed enhanced dissolution profi le, compared to both 
fenofi brate raw powder and Lipanthyl®. Solid state characterization employing the SEM, 
XRD and DSC studies indicated that the SEDDS/SNEDDS powder produced smooth gran-
ular particles in amorphous form.
In conclusion, solidifi cation using adsorbents is a powerful technique for the prepara-
tion of rapidly dissolving formulations of fenofi brate. The solidifi cation of SEDDS/SNEDDS 
using NUS2 improved the surface adsorption, porosity, anticaking fl ow enhancing proper-
ties and the ability to keep the drug stable in amorphous state, which could be one of the 
best carriers today to deliver poorly soluble drugs.
This approach could potentially lead to be er bioavailability of fenofi brate drug prod-
ucts. Conversion of a liquid self-emulsifying drug delivery system into a free fl owing 
solid powder using high surface inorganic materials (Neusilin US2) is one of the most re-
cent and promising approaches in pharmaceutical dosage systems. However, knowledge 
of the integrity of excipients is helpful in this regard, but it is ultimately necessary to test 
each formulation.
The infl uence of »drug-adsorbent formulation« interactions should be investigated on 
the case-by-case basis in any formulation.
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